Myles David C. 4

What Happened
Myles David, Olema Pharmaceuticals’ Chief Discovery & Non‑Clinical Development Officer, was granted two derivative equity awards on 2026-02-02 totaling 356,250 shares: a 250,000‑share option award and a 106,250‑share performance‑based option award. Both grants show $0 cash paid (awards issued, not purchased). These are option/award grants (transaction code A), not share sales or open‑market purchases.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (appears timely, within the usual two‑business‑day window).
• Awards: 250,000 shares (time‑based option) and 106,250 shares (performance‑based option) — total 356,250 derivative shares; price reported $0.00 (award/grant).
• Vesting (per footnotes):
  • Time‑based award: 25% vests on Feb 2, 2027, then 1/48 of total vests monthly thereafter, subject to continued service.
  • Performance award: eligible to vest across two performance periods (Feb 2, 2026–Dec 31, 2029 and Feb 2, 2026–Dec 31, 2030) if Olema’s stock reaches preset 30‑day average price thresholds; portions vest upon Compensation Committee certification and subject to continued service.
• Shares beneficially owned after transaction: not specified in the filing.

Context

• These are derivative grants (stock options/awards). They do not represent immediate share purchases or sales and only convert into shares if vesting conditions are met and options are exercised.
• Time‑based awards are standard retention incentives; performance awards vest only if specified stock price targets are achieved, so they are tied to the company’s future market performance.
• Such grants are routine compensation for executives and do not by themselves indicate insider buying or selling behavior.